Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Clazosentan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Clazosentan. Displaying page 1 of 1.
    EudraCT Number: 2018-000241-39 Sponsor Protocol Number: ID-054-304 Start Date*: 2018-08-27
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to...
    Medical condition: Aneurysmal Subarachnoid Hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10039330 Ruptured cerebral aneurysm PT
    21.1 10029205 - Nervous system disorders 10042316 Subarachnoid haemorrhage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) SE (Completed) FR (Completed) CZ (Completed) BE (Completed) DK (Completed) HU (Completed) AT (Completed) PL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006785-29 Sponsor Protocol Number: AC-054-302 Start Date*: 2009-09-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-caus...
    Medical condition: Indication: Subarachnoid aneurysmal hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    11 10042316 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) FI (Prematurely Ended) AT (Prematurely Ended) BE (Completed) CZ (Completed) FR (Completed) DE (Completed) SI (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002453-31 Sponsor Protocol Number: AC-054-201 Start Date*: 2005-02-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A Phase IIb, multi-center, international, double-blind, randomized, placebo-controlled, parallel-group, dose-finding study for the prevention of cerebral vasospasm after aneurysmal subarachnoid hem...
    Medical condition: Prevention of ischaemic complications related to vasospasm in patients with aneurysmal subarachnoid haemorrhage
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) FI (Completed) DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002584-27 Sponsor Protocol Number: AC-054-301 Start Date*: 2007-11-07
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-caus...
    Medical condition: Indication: Aneurysmal subarachnoid hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042318 Subarachnoid haemorrhage NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) FI (Completed) SE (Completed) DE (Completed) AT (Completed) DK (Completed) ES (Completed) CZ (Completed) IT (Completed) SI (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2015-002721-18 Sponsor Protocol Number: AC-054-203 Start Date*: 2016-02-17
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A prospective, multi-center, open-label, single-arm, Phase 2 study to assess the efficacy and safety of clazosentan in reversing angiographically-confirmed cerebral vasospasm in adult subjects with...
    Medical condition: Aneurysmal subarachnoid hemorrhage (aSAH); cerebral vasospasm
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10047164 Vasospasm cerebral LLT
    19.1 100000004863 10042320 Subarachnoid hemorrhage LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 06:58:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA